abrdn Life Sciences Investors Q1 2025 Commentary
Source: SeekingAlpha
2025-05-31 00:20:00 ET
Summary
- The equity portion of the Fund fell (gross of fees) and underperformed its benchmark, the NASDAQ Biotechnology Index.
- During the first quarter of 2025, we made several changes to the portfolio.
- With Donald Trump securing his second term, uncertainty around election results has been replaced with policy ambiguity.
Fund performance
Read the full article on Seeking Alpha
For further details see:
abrdn Life Sciences Investors Q1 2025 Commentary
abrdn Focused U.S. Small Cap Active ETF
NASDAQ: AFSC
AFSC Trading
-1.28% G/L:
$30.90 Last:
103 Volume:
$30.90 Open:
